אפיניטור 5 מג Израиль - иврит - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 10 מג Израиль - иврит - Ministry of Health

אפיניטור 10 מג

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 2.5 מג Израиль - иврит - Ministry of Health

אפיניטור 2.5 מג

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

קסאומין 100 Израиль - иврит - Ministry of Health

קסאומין 100

alphamedix ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 0.8 ng 100 ld50 units / vial - botulinum toxin

קסאומין 50 Израиль - иврит - Ministry of Health

קסאומין 50

alphamedix ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 0.2 - 0.4 ng 50 ld50 units / vial - botulinum toxin

הייפרטט אסדי Израиль - иврит - Ministry of Health

הייפרטט אסדי

padagis israel agencies ltd, israel - tetanus immune globulin (s/d treated) - תמיסה להזרקה - tetanus immune globulin (s/d treated) 250 u/ml - tetanus immunoglobulin - tetanus immunoglobulin - immunity against tetanus toxin. treatment of active cases of tetanus.

רמסימה 100 מג תוך-ורידי Израиль - иврит - Ministry of Health

רמסימה 100 מג תוך-ורידי

padagis israel agencies ltd, israel - infliximab - אבקה להכנת תמיסה מרוכזת לעירוי - infliximab 100 mg/vial - infliximab

אקטיק 200 מקג Израиль - иврит - Ministry of Health

אקטיק 200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 600 מקג Израиль - иврит - Ministry of Health

אקטיק 600 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 1200 מקג Израиль - иврит - Ministry of Health

אקטיק 1200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.